Response to initial treatment of low and intermediate risk gestational trophoblastic disease with methotrexate and folinic acid.
Artículo
en Inglés
| IMSEAR
| ID: sea-38856
ABSTRACT
OBJECTIVES:
To evaluate the response and toxicity of methotrexate and folinic acid given as primary treatment of low and intermediate risk gestational trophoblastic disease (GTD). MATERIAL ANDMETHOD:
Medical records review was performed in patients who received methotrexate and folinic acid as a primary treatment of low and intermediate risk persistent GTD between January 1992 and December 2001. Response was defined as decline of beta human chorionic gonadotropin (hCG) to < or = 5 mlU/ml (remission) after methotrexate and folinic acid treatment. Response rate was estimated and factors associated with response were evaluated.RESULTS:
Ninety four eligible patients were treated with intramuscular methotrexate and folinic acid. Complete remission was achieved in 64 cases (68%, 95% CI 58-78%). Mucositis (6.4%) and hepatotoxicity (6.4%) were the most common toxicity of methotrexate in the present study and none of these toxic effects was life threatening. Factors associated with response were initial serum hCG < or = 10,000 mlU/ml and stage I disease.CONCLUSION:
Methotrexate with folinic acid is effective treatment for low and intermediate risk GTD with minimal severe toxicity.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Complejo Vitamínico B
/
Femenino
/
Humanos
/
Embarazo
/
Metotrexato
/
Leucovorina
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Adulto
/
Enfermedad Trofoblástica Gestacional
Tipo de estudio:
Estudio de etiología
/
Estudio observacional
/
Factores de riesgo
Idioma:
Inglés
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS